of this proposed rule, we discussed drugs covered as additional preventive services (henceforth DCAPS drugs, for the ease of the reader)
CMS proposes at proposed 427.501(d)(1), to conduct a reconciliation 12 months after issuance of the subsequent Rebate Report specified in 427.501(c) to include any restatements that have occurred in the drug pricing data and claims billing data reported to CMS and used in the rebate calculation specified in subpart D of the part
Overall, these modifications address MDPP supplier and beneficiary needs based upon available monitoring and evaluation data received to date, feedback from Medicare Advantage plans and existing MDPP suppliers, and feedback from beneficiary focus groups
In the event that we later determine that the payment model established under section 1899(i)(3) of the Act no longer meets this requirement, we would undertake additional notice and comment rulemaking to make adjustments to the payment model to assure continued compliance with the statutory requirements
Bureau of Labor Statistics (BLS) data, as they produce indexes that best meet the criteria of reliability, timeliness, availability, and relevance, and group them into one of the following BLS categories: Employment Cost Indexes
